Unknown

Dataset Information

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.


ABSTRACT:

Introduction

Although PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecule expressed in T cells, which could enhance T cell proliferation and activation. Herein, the synergetic antitumor effect and underlying mechanism of 4-1BB agonist combined with PD-1/PD-L1 blockade were determined in B-cell lymphoma (BCL).

Methods

Subcutaneous transplantation BCL tumor models and metastasis models were established to evaluate the therapeutic effect of PD-L1 antibody and/or 4-1BB agonist in vivo. For the mechanistic study, RNA-seq was applied to analyze the tumor microenvironment and immune-related signal pathway

SUBMITTER: Wang Y 

PROVIDER: S-EPMC9762552 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature